Antyra Inc.

Other

Novo Nordisk A/s

Dgi Biotechnologies, Inc.

Renee Brissette

Wlodek Mandecki

Jane Spetzler

Neil I Goldstein

Jakob Brandt

Arthur J Blume

Renuka Pillutla

Juan Carcamo

Olga Dedova

Pauline M Tang

Per Hertz Hansen

Hao Liu

Ku-chuan Hsiao

John Prendergast

Søren Østergaard

Lauge Schäffer

Michael Spruyt

Paul Fletcher

Michael Lennick

Pinger Wang

James Beasley

Weiqing Cheng

Mark Ravera

Ku-Chuan Hsiao

Wlodek S Mandecki

Sören Östergaard

Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonist peptides may also be developed as therapeutics.

Insulin and IGF-1 receptor agonists and antagonists

The present invention provides peptides that bind to the active site of the growth hormone receptor. The present invention also provides methods of using these peptides to identify small organic molecules, which are novel agonists or antagonists of the growth hormone receptor. In addition, the present invention provides kits and therapeutic compositions comprising the peptides that bind to growth hormone receptor.

Compounds that bind to growth hormone receptor

The invention relates to a modified phage display method for detecting and identifying target and target binders. The modified methods involve transforming host cells with two separate phages of a target or target library and a target-binder library, and selecting to eliminate the non-paired targets and binders. The invention also relates to antibodies that bind to complexes of target and target binders; nucleic acids encoding target and target binders peptides; and the use of sequence information inherent in the targets and target binders for target validation using in silico approaches. The invention further relates to diagnostics and therapeutics employing the disclosed target and target binder peptides or polynucletides and their use in small molecule drug discovery; diagnostic and therapeutic applications directed to cancers and similar disorders; and site directed assays for high throughput drug screening.

Target specific screening and its use for identifying target binders

Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.

Compounds that bind growth to hormone receptor

Growing community of inventors

Clarksburg, NJ, United States of America

Renee Brissette